Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cogent Biosciences Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.cogentbio.com/
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Andrew R. Robbins, MBA
Number Of Employees: 205
Enterprise Value: $651,071,566
PE Ratio: -2.16
Exchange/Ticker 1: NASDAQ:COGT
Exchange/Ticker 2: N/A
Latest Market Cap: $606,820,480
BioCentury | Nov 5, 2024
Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
BioCentury | May 29, 2024
Management Tracks
Nurix promotes O’Connor to CMO, Phiasivongsa to CTO
Plus: NodThera names Daniel Swisher CEO, and updates from Cogent, Sapreme and Biocom
BioCentury | Feb 17, 2024
Finance
Public equity report: Five follow-ons total $875M+, PIPEs keep flowing
Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Dec 12, 2023
Deals
Dec. 11 Quick Takes: BMS paying $800M up front for SystImmune’s bispecific ADC
Plus: Pain, hearing loss company Hoba raises €23M and more from Novartis, Cogent and Zafrens
BioCentury | Jun 8, 2023
Data Byte
May brings year’s strongest follow-on activity to date
18 biopharmas raised $2.2B, with Guardant and ImmunoGen each raising over $300M
BioCentury | Jul 8, 2022
Finance
Looking for light at the end of biotech’s bear tunnel
3Q22 Financial Markets Preview: As pain grinds on, signals that biotech may be on road to recovery
BioCentury | Jul 5, 2022
Data Byte
Follow-ons perk up in June, but still well shy of last year’s haul
Ten biotechs raised almost $1 billion in follow-ons in June 2022
BioCentury | Jun 10, 2022
Product Development
Cogent’s first clinical readout in systemic mastocytosis drives stock bump
Ex-Array team believes in-licensed therapy can be best-in-class in hematological disorder
BioCentury | May 4, 2021
Management Tracks
Guardant unveils Eagle as CMO; plus Karyopharm, Arix, Eagle, Gemini, Neoleukin, MEI, Krystal, Relay and more
Cancer diagnostics company Guardant Health Inc. (NASDAQ:GH) hired Craig Eagle as CMO. Eagle, who was most recently was VP of medical affairs oncology at Genentech Inc., is a 19-year veteran of
Items per page:
1 - 10 of 23